Clinical Trial Update: Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating OTD70DERM for radiodermatitis caused by radiotherapy in head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• OTD70DERM

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Head and Neck Carcinoma | Phase 3 | Status: COMPLETED